Eye on Pharma: Prestige BioPharma, Alvogen Reach Commercialization Agreement for Trastuzumab Biosimilar
Prestige BioPharma and Alvogen have recently announced that they have entered into an exclusive partnership for the commercialization of Prestige BioPharma’s trastuzumab biosimilarin Central and Eastern Europe.
Prestige BioPharma and Alvogen have recently announced that they have entered into an exclusive partnership for the commercialization of Prestige BioPharma’s trastuzumab biosimilar in Central and Eastern Europe.
The proposed trastuzumab biosimilar will be seeking indications to treat human epidermal receptor 2 (HER2)-positive breast cancer, as well as HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The potential biosimilar is currently in phase 3 clinical development and will be marketed as Hervelous.
“I am pleased to partner with Prestige BioPharma to further expand our biosimilar portfolio in the region… We have managed to secure a leading position in biosimilars in the region, with a robust portfolio of leading molecules for the treatment of oncology, rheumatoid arthritis, and anemia and the expected addition of [a] trastuzumab biosimilar will be a great addition to our biosimilar assets,” commented Hacho Hatchikian, executive vice president of Alvogen.
The agreement includes the exclusive rights for Alvogen to commercialize the proposed biosimilar in all of its Central and Eastern European markets. Although the exact terms of the arrangement have not been publicly disclosed, Prestige BioPharma will assume the responsibility of development and product registration with the European Medicines Agency (EMA), as well as the commercial supply of the biosimilar out of its manufacturing facilities in Osong, South Korea.
The companies plan to file with the EMA and the FDA for regulatory approval in 2019.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.
